Skip to main content

Table 2 Subsequent therapies

From: Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

  IPI-treated cohort Non-IPI–treated cohort
IPI-noOther (n = 780)a IPI-Other (n = 314) Other-Other (n = 205) Other-IPI (n = 57)
Systemic therapy, no. (%) 0 313 (100) 54 (26) 57 (100)
 Immunotherapy 0 181 (58) 18 (9) 57 (100)
  Anti–PD-1 agentb 0 161 (51) 18 (9) 10 (18)
  Anti–CTLA-4 agentc 0 34 (11) 0 57 (100)
 Other systemic therapy, no. (%) 0 186 (59) 43 (21) 15 (26)
  BRAF ± MEK inhibitord 0 103 (33) 18 (9) 8 (14)
  Chemotherapye 0 110 (35) 33 (16) 12 (21)
  Other investigational agentf 0 11 (4) 1 (<1) 0
  Otherg 0 11 (4) 0 0
Radiotherapyh 138 (18) 101 (32) 21 (10) 16 (28)
  1. CTLA-4 cytotoxic T-lymphocyte antigen 4, IPI ipilimumab, PD-1 programmed death 1.
  2. aRadiotherapy was allowed with ipilimumab in this cohort; therefore, it was not considered subsequent therapy
  3. bPembrolizumab or nivolumab
  4. cIpilimumab
  5. dDabrafenib ± trametinib or vemurafenib ± cobimetinib
  6. eBleomycin, carboplatin, cisplatin, combinations of antineoplastic agents, cyclophosphamide, dacarbazine, dactinomycin, docetaxel, etoposide, fotemustine, gemcitabine, lomustine, melphalan, paclitaxel, paclitaxel + carboplatin, temozolomide, treosulfan, trofosfamide, vinblastine, vincristine, vindesine, or vinorelbine
  7. fBevacizumab or imatinib
  8. gAldesleukin, antineoplastic and immunomodulating agents, interferon-alpha, interleukin-2, melanoma vaccine, other therapeutic products, or monoclonal antibodies
  9. hRadiation, radiosurgery, radiotherapy, or yttrium (90Y)